New targets for therapy in breast cancer

Stephen RD Johnston

New targets for therapy in breast cancer: Farnesyltransferase inhibitors

Current systemic therapies for breast cancer are often limited by their nonspecific mechanism of action, unwanted toxicities on normal tissues, and short-term efficacy due to the emergence of drug resistance. ...

Authors: Julia Head and Stephen RD Johnston

Citation: Breast Cancer Research 2004 6:262

Content type: Review Published on: 6 October 2004
- View Full Text
- View PDF
New targets for therapy in breast cancer: Mammalian target of rapamycin (mTOR) antagonists

Mammalian target of rapamycin (mTOR) is a serine-threonine kinase member of the cellular phosphatidylinositol 3-kinase (PI3K) pathway, which is involved in multiple biologic functions such as transcriptional a...

Authors: Hetty Carraway and Manuel Hidalgo

Citation: Breast Cancer Research 2004 6:219

Content type: Review Published on: 12 August 2004
- View Full Text
- View PDF
New targets for therapy in breast cancer: Small molecule tyrosine kinase inhibitors

Over the past several years many advances have been made in our understanding of critical pathways involved in carcinogenesis and tumor growth. These advances have led to the investigation of small molecule in...

Authors: Nancy U Lin and Eric P Winer

Citation: Breast Cancer Research 2004 6:204

Content type: Review Published on: 29 July 2004
- View Full Text
- View PDF